Basics |
X4 Pharmaceuticals Inc
Arsanis Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of monoclonal antibodies for the targeted immunotherapy of serious infections.
|
IPO Date: |
May 13, 2022 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$5.5M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.07 | 5.20%
|
Avg Daily Range (30 D): |
$0.04 | 5.54%
|
Avg Daily Range (90 D): |
$0.05 | 4.54%
|
Institutional Daily Volume |
Avg Daily Volume: |
.56M |
Avg Daily Volume (30 D): |
.22M |
Avg Daily Volume (90 D): |
.48M |
Trade Size |
Avg Trade Size (Sh.): |
230 |
Avg Trade Size (Sh.) (30 D): |
356 |
Avg Trade Size (Sh.) (90 D): |
301 |
Institutional Trades |
Total Inst.Trades: |
10 |
Avg Inst. Trade: |
$.93M |
Avg Inst. Trade (30 D): |
$2.54M |
Avg Inst. Trade (90 D): |
$2.54M |
Avg Inst. Trade Volume: |
.18M |
Avg Inst. Trades (Per Day): |
5 |
Market Closing Trades |
Avg Closing Trade: |
$.53M |
Avg Closing Trade (30 D): |
$M |
Avg Closing Trade (90 D): |
$M |
Avg Closing Volume: |
142.9K |
|
|
|
|
Financials |
|
TTM |
Q4 2024 |
FY 2024 |
Basic EPS
|
$-.85
|
$-.26
|
$-.85
|
Diluted EPS
|
$-.85
|
$-.26
|
$-.85
|
Revenue
|
$ 7.76M
|
$ 1.06M
|
$ 7.76M
|
Gross Profit
|
$ 4.27M
|
$ .36M
|
$ 4.27M
|
Net Income / Loss
|
$ -4.37M
|
$ -1.8M
|
$ -4.37M
|
Operating Income / Loss
|
$ -3.76M
|
$ -1.64M
|
$ -3.76M
|
Cost of Revenue
|
$ 3.49M
|
$ .7M
|
$ 3.49M
|
Net Cash Flow
|
$ -3.25M
|
$ -.27M
|
$ -3.25M
|
PE Ratio
|
|
|
|
Splits |
Apr 19, 2023:
10:1
|
Mar 14, 2019:
6:1
|
|